J Audiol Otol Search

CLOSE


J Audiol Otol > Epub ahead of print
Jasmine, Ghani, Yuniartiningtyas, and Ratih: Effectiveness of Intratympanic Steroid Injection on Hearing Threshold Improvement in Sudden Sensorineural Hearing Loss: A Meta-Analysis

Abstract

Background and Objectives

Sudden sensorineural hearing loss (SSNHL) is an otological emergency requiring early intervention to prevent permanent hearing impairment. Although recent studies have reported the effectiveness of intratympanic steroid injection (ITSI), evidence supporting its consistency across different clinical contexts remains limited. To evaluate the effectiveness of ITSI in improving hearing threshold(s) in patients diagnosed with SSNHL, and to examine whether treatment outcomes differ according to baseline hearing loss severity, clinical phenotype, and therapeutic role.

Materials and Methods

A quantitative meta-analysis of 16 eligible studies was performed. Pooled effect sizes were calculated using a random-effects model, with treatment effects expressed as Hedges’ g, and publication bias was assessed using Egger’s regression test. Subgroup analyses were performed based on the severity of initial hearing loss, presence of clinical comorbidities, and therapeutic strategy (primary versus salvage therapy). Differences with p≤0.05 were considered to be statistically significant.

Results

ITSI significantly improved hearing thresholds, with a large pooled effect size (Hedges’ g=-1.05; p<0.05). Egger’s test indicated no significant publication bias (p=0.07). Subgroup analyses revealed no significant differences in treatment effectiveness between moderate-to-severe and severe baseline hearing loss (p=0.20), or among the various clinical phenotypes (p=0.63). However, ITSI demonstrated greater effectiveness when used as primary therapy (Hedges’ g= -1.24) compared with salvage therapy (Hedges’ g=-0.59).

Conclusions

ITSI was an effective intervention to improve hearing thresholds in patients with SSNHL. Treatment outcomes were not significantly influenced by baseline hearing loss severity or clinical phenotype, but were affected by the therapeutic role. Early use of ITSI as first-line therapy yielded the most optimal hearing recovery while remaining a valuable salvage option.

Introduction

Sudden sensorineural hearing loss (SSNHL), commonly referred to as sudden deafness, is regarded as a medical emergency in otology due to its potential to cause irreversible auditory impairment. The condition is clinically defined as a sensorineural hearing loss of ≥30 dB affecting at least three consecutive frequencies within a 72-hour period [1]. SSNHL is widely considered a multifactorial disorder, with proposed etiologies including viral infections, vascular compromise, autoimmune mechanisms, trauma, congenital inner ear anomalies, smoking, severe psychological stress, and central nervous system pathologies such as acoustic tumors [2]. SSNHL is an otologic condition with a variable global incidence. In the United States, the reported annual incidence ranges between 5 and 27 per 100,000 population [3], whereas data from Germany (2004–2011) indicate higher estimates, ranging from 20 to 400 per 100,000 individuals [4]. Hearing loss exerts a substantial impact not only on affected individuals’ quality of life but also on their communication partners. Previous evidence indicates that such maladaptive behaviors account for approximately 26.7% of the perceived disability burden experienced by close family members or significant others [5]. Beyond its psychosocial consequences, untreated hearing loss has been increasingly recognized as an independent and potentially modifiable risk factor for cognitive decline and dementia [6]. Collectively, these considerations highlight the urgency of early therapeutic intervention. In cases of SSNHL, prompt diagnosis and immediate treatment initiation are key prognostic factors influencing the likelihood of hearing recovery.
Corticosteroids remain the cornerstone of therapy for SSNHL and may be administered either systemically or locally via intratympanic steroid injection (ITSI). In Otolaryngology-Head and Neck Surgery, oral corticosteroids represent a fundamental component of medical management and are widely prescribed for conditions such as chronic rhinosinusitis, SSNHL, and idiopathic facial nerve paralysis (Bell’s palsy) [7]. According to the 2019 clinical practice guidelines issued by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), both systemic and intratympanic corticosteroid therapies are recommended as first-line treatment options for SSNHL [1]. The therapeutic efficacy of corticosteroids is mediated through multiple mechanisms, including anti-inflammatory and immunosuppressive effects, stabilization of cellular membranes, modulation of ionic homeostasis, and enhancement of cochlear microcirculation [8,9]. Notably, vascular compromise has been implicated as a central pathophysiological mechanism underlying SSNHL. Experimental evidence suggests that corticosteroid administration may improve cochlear blood flow and attenuate ischemia-related inner ear injury [10,11]. Collectively, these mechanisms provide a strong biological rationale for the widespread use of corticosteroids in the management of SSNHL.
Despite their established efficacy, systemic corticosteroids are associated with significant adverse effects, particularly in patients with underlying comorbidities. Oral corticosteroid administration is associated with potential adverse effects, including reactivation of latent infections, contraindications in pregnancy, worsening of cardiovascular comorbidities (e.g., hypertension), and dysregulation of glycaemic control in patients with diabetes mellitus [12-14]. Furthermore, prolonged or high-dose systemic corticosteroid use has been linked to serious complications, including osteonecrosis, pancreatitis, and steroid-induced myopathy [15,16]. These limitations have prompted increasing interest in alternative routes of corticosteroid administration that minimize systemic exposure.
Several studies have reported superior or comparable hearing outcomes with ITSI compared to systemic steroid therapy, particularly in patients who are unsuitable for high-dose systemic treatment due to metabolic or systemic risks. ITSI allows for direct delivery of corticosteroids to the inner ear, achieving higher local drug concentrations while reducing systemic absorption and associated adverse [17-19]. This approach has been implemented in countries such as the United States, reflecting its international adoption in clinical practice [20]. Consequently, this approach has emerged as a therapeutic alternative for patients who are unable to receive high-dose systemic corticosteroids due to the risk of metabolic complications [21]. Nevertheless, despite its theoretical and clinical advantages, the reported effectiveness of ITSI in improving hearing thresholds among patients with SSNHL remains inconsistent across studies. Variability in treatment protocols, including differences in corticosteroid type, dosage concentration, injection frequency, and timing of administration may contribute to heterogeneity in reported outcomes. To comprehensively evaluate the consistency of therapeutic effects, an evidence-based synthesis is required.
This meta-analysis aims to systematically evaluate the effectiveness of ITSI in improving hearing thresholds among patients with SSNHL. Hearing outcomes were assessed using changes in Pure Tone Average (PTA), expressed in dB, based on mean pre- and post-intervention values. Additionally, subgroup analyses were conducted to explore potential differences in treatment effects according to baseline hearing loss severity, clinical phenotypes of SSNHL, and the role of ITSI as either primary (first-line) or salvage therapy.

Materials and Methods

Literature search

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. A comprehensive literature search was performed independently by the authors over a period of 20 days to identify relevant scientific publications examining the effectiveness of ITSI in reducing hearing thresholds among patients with SSNHL.
Electronic searches were conducted across three international databases: Scopus, ScienceDirect, and PubMed. The search strategy employed a combination of Medical Subject Headings terms and free-text keywords, including “Sudden Sensorineural Hearing Loss,� “SSNHL,� “Sudden Deafness,� “Intratympanic Steroid Injection,� “Intratympanic,� and “Steroid.� Searches were limited to peer-reviewed international articles published between 2021 and 2026, in order to ensure the inclusion of the most up-to-date evidence.

Eligibility criteria

All scientific articles found will be selected in detail based on inclusion criteria. Relevant articles that meet the inclusion criteria will be included in this study. The inclusion criteria used are: 1) International scientific articles, 2) Articles published within the last 5 years (2021–2026), 3) The research subjects are patients with sudden deafness or SSNHL, 4) The subjects received an intervention in the form of an ITSI, 5) The outcome measures used were hearing threshold measurements using PTA to calculate the mean hearing level before and after the intervention, and 6) The study results data involved the mean and standard deviation before and after the intervention.
In this study, PTA was used to evaluate patients’ hearing thresholds. PTA refers to the average hearing threshold measured across specific frequencies and is commonly employed to assess the degree of hearing loss in patients [22]. The exclusion criteria established in this meta-analysis include: 1) Conference abstracts, notes, letters, and review articles, 2) Articles published before 2021, and 3) Scientific articles that do not include data before and after the intervention.

Data extraction

All eligible studies were independently extracted by the authors. Extracted data were categorized to provide both analytical and clinical context for the meta-analysis. The primary descriptive variables included study title, country of origin, presence of clinical phenotypes, therapeutic role of ITSI (primary/first-line or salvage therapy), average baseline hearing loss severity, type of intervention, and study duration.
For statistical analysis, the following quantitative variables were extracted: 1) Sample size (n) of each study, 2) Mean hearing threshold values before (pre-intervention) and after (post-intervention) ITSI, and 3) Standard deviations of hearing thresholds before and after ITSI intervention.

Statistical analysis

All eligible studies were analyzed using Stata Statistical Software, Release 17 (StataCorp LLC., College Station). Hearing threshold outcomes were consistently reported in dB across all included studies. The statistical analysis commenced with an assessment of between-study heterogeneity using the I2 statistic. An I2 value of ≤25% was interpreted as indicating low heterogeneity among comparable studies, in which case a fixed-effect model was applied. Conversely, I2 values of 50% and 75% were considered to represent moderate and high heterogeneity, respectively, indicating substantial variability; therefore, a random-effects model was employed [23]. Subsequent analyses were conducted using the selected statistical model. The magnitude of the intervention effect was estimated using Hedges’ g effect size, which provides an unbiased standardized mean difference, particularly suitable for studies with small sample sizes.
To ensure the robustness and validity of the meta-analysis findings, publication bias was assessed using the Egger test. The null hypothesis (H0) assumed the absence of publication bias or small-study effects. A p-value greater than the predetermined significance level (α=0.05) indicated no evidence of publication bias, whereas a p-value less than α suggested the presence of publication bias.
In addition, subgroup analyses were performed to evaluate the influence of baseline hearing loss severity, the presence of clinical phenotypes, and the therapeutic role of the intervention on the effectiveness of ITSI in reducing hearing thresholds among patients with SSNHL. All statistical analyses were conducted using a two-tailed significance level of 5% (α=0.05).

Results

Literature search result

Fig. 1 illustrates the PRISMA flow diagram summarizing the literature identification and selection process. A comprehensive search of the Scopus, ScienceDirect, and PubMed databases yielded 184 records relevant to the predefined keywords. After title and abstract screening, 103 articles were retained for further evaluation, while 81 records were excluded. Subsequent screening resulted in the exclusion of 48 articles that did not meet the inclusion criteria, leaving 55 studies eligible for full-text assessment.
At the eligibility stage, 45 full-text articles were excluded. Of these, 27 studies lacked essential quantitative data, specifically mean hearing threshold values or PTA standard deviations, while 18 studies were excluded for other methodological reasons, including the use of Siegel criteria without accompanying numerical PTA data. In addition, four relevant studies were identified through manual searching.
Ultimately, 14 studies met all inclusion criteria and were included in the meta-analysis. Notably, several publications (e.g., Kanotra, et al. [13] and Kuo, et al. [24]) reported outcomes from multiple independent participant groups within a single study. To ensure methodological rigor and accurate estimation of intervention effects, these datasets were extracted and analyzed as 16 independent units in the quantitative synthesis.

Characteristics of the studies

All based on Table 1, most of the included studies were conducted in Asia, predominantly in Taiwan, China, and Japan. A total of 14 studies met the inclusion criteria [25-32]. The baseline severity of hearing loss was mainly classified as severe, as reported in 11 studies. Regarding clinical phenotype, four studies specifically evaluated homogeneous patient populations with distinct comorbidities, including hepatitis B [33], diabetes mellitus [34], labyrinthitis [35], and arterial stiffness [36]. In addition, differences in therapeutic strategies, namely primary versus salvage ITSI, were analyzed to assess variations in treatment effectiveness across different stages of SSNHL management.
During data extraction, a discrepancy was observed between the number of eligible publications and the number of units included in the quantitative synthesis. Although 14 articles fulfilled the inclusion criteria, the meta-analysis incorporated 16 independent analytical units. This discrepancy arose because two studies, Kanotra, et al. [13] and Kuo, et al. [24], each reported outcomes from two distinct and independent patient cohorts within a single publication. These cohorts, such as primary (first-line) and salvage therapy groups, differed in clinical characteristics and provided separate numerical data (means and standard deviations), thereby warranting independent inclusion in the meta-analytic model.

Statistical analysis

In this study, several statistical analyses were performed, including estimation of the overall effect size, assessment of publication bias, and subgroup analyses. The effect size analysis was conducted to determine the overall therapeutic impact of the intervention, while publication bias testing and subgroup analyses were used to evaluate potential bias and to explore sources of heterogeneity across studies. Collectively, these analyses provide a comprehensive and objective interpretation of the findings.

Overall effect size analysis

All studies meeting the inclusion criteria compared hearing thresholds before and after treatment. The effect size was expressed using Hedges’ g to account for small-sample bias. Based on the quantitative synthesis of 16 analytical units, ITSI demonstrated a statistically significant effect in reducing hearing thresholds among patients with SSNHL. As illustrated in the forest plot (Fig. 2), the pooled effect size was -1.05.
According to Cohen’s classification, an absolute Hedges’ g value greater than 0.80 represents a large effect size. The negative direction of the effect indicates a lower post-treatment hearing threshold compared with the pre-treatment condition, reflecting an improvement in hearing function following intervention. These findings provide strong evidence that ITSI significantly reduces hearing thresholds in patients with SSNHL compared with baseline measurements. the consistency of therapeutic effects, an evidence-based synthesis is required.
Table 2 shows the results of testing the overall heterogeneity of the scientific literature. Based on the test results, a value I2 of 95.41% was obtained with p<0.01 (α [0.05]). This indicates a very high degree of heterogeneity among the various studies, so the effect size was combined using a random-effects model. The two-tailed test results showed p<0.01 (α [0.05]). Based on the test output, it can be concluded that the combined effect size obtained is statistically significant. The 95% confidence interval (CI) ranged from -1.45 to -0.65 and did not cross zero, indicating a consistent and robust intervention effect across studies despite substantial between-study variability.

Publication bias

Fig. 3 illustrates the funnel plot for publication bias assessment. Visual inspection indicates that the distribution of study estimates is not completely symmetrical around the pooled effect size line (θ). Most studies are clustered on the right side of the pooled effect, while fewer studies appear on the left side. This asymmetrical pattern suggests the potential presence of publication bias or small-study effects, whereby studies with smaller sample sizes and non-significant results are less likely to be published. Therefore, a formal statistical assessment was performed using Egger’s regression test to further evaluate the presence of publication bias.
The results of Egger’s regression test are presented in Table 3. The regression coefficient (B1) was -3.51 with a standard error of 1.929, yielding a p-value of 0.07, which exceeds the predefined significance level (α=0.05). Consequently, the null hypothesis (H0), stating that no publication bias or small-study effects exist, could not be rejected.
These findings indicate that there is no statistically significant evidence of publication bias in this meta-analysis. Accordingly, the pooled effect estimate of ITSI effectiveness (Hedges’ g=-1.05) can be considered representative and is unlikely to be substantially influenced by the non-publication of studies with non-significant results.

Subgroup analysis

Subgroup analyses were performed based on initial hearing loss severity, clinical phenotype, and treatment strategy (primary vs salvage) to assess the consistency of ITSI effectiveness across different patient populations.

Based on average initial hearing loss level

In this study, the mean initial hearing loss was extracted from the pre-intervention mean hearing threshold reported in each included study. Based on the American Speech–Language–Hearing Association guidelines adapted from Clark [37], the degree of hearing loss was classified into seven categories according to specific dB intervals. The degree of deafness was categorized based on PTA thresholds as follows: normal (-10 to 15 dB), slight (16 to 25 dB), mild (26 to 40 dB), moderate (41 to 55 dB), moderately severe (56 to 70 dB), severe (71 to 90 dB), and profound (>90 dB) hearing loss.
Among the 16 included studies, most reported a mean initial hearing loss in the severe category (11 studies), followed by moderately severe (3 studies) and moderate (2 studies). For subgroup analysis, the moderately severe and severe categories were consolidated due to the limited number of studies in each group. Category 0 comprised studies with moderate-to-severe initial hearing loss (≤70 dB), while category 1 included studies with severe initial hearing loss (>70 dB). The corresponding forest plot is presented in Fig. 4.
As shown in Table 4, category 0 demonstrated a pooled effect size of -1.53 with a 95% CI ranging from -2.60 to -0.46, indicating a large and statistically significant effect. This subgroup exhibited substantial heterogeneity (I2=95.97%, p<0.01). Category 1 showed a smaller but still statistically significant pooled effect size (Hedges’ g=-0.80; 95% CI: -1.08 to -0.53), with high heterogeneity (I2=87.52%, p<0.01).
The test for subgroup differences revealed a Qb (1) value of 1.64 with a p-value of 0.20. As the p-value exceeded the significance threshold (α=0.05), no statistically significant difference was observed between the two subgroups. These findings indicate that the effectiveness of ITSI is not significantly influenced by the severity of initial hearing loss, and that ITSI provides comparable hearing improvement across different baseline levels of hearing impairment.

Based on clinical phenotype

The second subgroup analysis evaluated the impact of clinical phenotypes on the effectiveness of ITSI. Clinical phenotype was defined as studies involving homogeneous patient populations with specific comorbid conditions. Category 0 included studies without defined clinical phenotypes (12 studies), whereas category 1 comprised studies involving patients with specific phenotypes (4 studies), including hepatitis B virus and diabetes mellitus [33,34], labyrinthitis [34], and arterial stiffness [36].
Based on Fig. 5 and Table 5, studies without clinical phenotypes (category 0) demonstrated a pooled effect size of -0.96 (95% CI: -1.33 to -0.59). The absolute Hedges’ g value exceeding 0.8 indicates a large and statistically significant treatment effect, despite substantial heterogeneity (I2=92.22%). Studies involving specific clinical phenotypes (category 1) showed a relatively larger pooled effect size (Hedges’ g=-1.28), confirming that ITSI significantly reduced hearing thresholds in both subgroups of SSNHL patients.
To assess differences between subgroups, a test of group differences was performed. The results showed a Qb (1) value of 0.23 with a p-value of 0.63, exceeding the significance threshold (α=0.05). These findings indicate no statistically significant difference in ITSI effectiveness between studies with or without clinical phenotypes, suggesting that the therapeutic benefit of ITSI remains consistent regardless of the presence of comorbid clinical conditions.

Based on type of therapy

In this meta-analysis, a subgroup analysis based on treatment strategy was conducted to evaluate differences in the effectiveness of ITSI across different stages of clinical management. Treatment strategies were classified into primary/firstline therapy and salvage therapy. Primary/first-line therapy was defined as ITSI administered as the initial intervention following diagnosis, prior to the use of any other therapeutic modalities. In contrast, salvage therapy referred to ITSI administered after failure or suboptimal response to initial treatment.
Primary (first-line) therapy was defined as ITSI administered as the initial therapeutic intervention immediately following the diagnosis of SSNHL, without prior exposure to systemic corticosteroids or other adjunctive treatment modalities [38]. Salvage therapy was defined as ITSI administered after an inadequate, incomplete, or absent hearing recovery following initial treatment, most commonly systemic corticosteroid therapy [1,39]. For studies evaluating salvage ITSI, hearing threshold improvement was extracted based on the hearing thresholds reported immediately before initiation of salvage ITSI, following completion of prior treatment, and after completion of salvage ITSI, as defined in the original studies.
Fig. 6 presents the forest plot of ITSI effects on hearing thresholds according to treatment strategy. The results of the subgroup analysis are summarized in Table 6. The primary/first-line therapy subgroup comprised 10 studies and demonstrated a pooled effect size of Hedges’ g=-1.24 (95% CI: -1.83 to -0.66), indicating a large and statistically significant effect. This subgroup exhibited substantial heterogeneity, with an I2 value of 96.26% (p<0.01), suggesting considerable variability in effect estimates across studies.
The salvage therapy subgroup included 6 studies and showed a smaller pooled effect size of Hedges’ g=-0.59 (95% CI: -0.74 to -0.44), corresponding to a moderate but statistically significant improvement in hearing thresholds among patients with SSNHL. Notably, heterogeneity in this subgroup was low (I2=14.80%), indicating greater consistency across studies.
The test for subgroup differences revealed a statistically significant difference between treatment strategies, with Qb (1)=4.45 and p=0.03. This finding indicates that ITSI administered as primary/first-line therapy provides a significantly greater improvement in hearing thresholds compared with its use as salvage therapy.

Discussion

ITSI has been utilized in clinical practice since its initial introduction in 1986 [40]. The comparative effectiveness of intratympanic versus systemic corticosteroid therapy remains an important consideration in clinical practice. Han, et al. [41] found that intratympanic steroids provide therapeutic efficacy equivalent to systemic corticosteroids in patients with sudden hearing loss. Preclinical evidence further supports the pharmacokinetic advantage of ITSI, as intratympanic administration achieves significantly higher steroid concentrations within the cochlea compared to systemic delivery. This localized approach not only maximizes therapeutic effects at the target site but also minimizes systemic adverse events associated with oral or intravenous corticosteroids [42]. Nevertheless, robust scientific evidence derived from pre- and post-intervention intratympanic studies evaluating changes in hearing thresholds remains relatively limited. The findings of the present meta-analysis strengthen the existing evidence supporting the effectiveness of intratympanic corticosteroid administration in reducing hearing thresholds and improving auditory function in patients with SSNHL.
Pooled effect size analysis of 16 included studies demonstrated a Hedges’ g of -1.05, indicating a large and clinically meaningful treatment effect. This result suggests that ITSI is associated with a substantial improvement in hearing thresholds when compared with pre-intervention baseline measurements, thereby supporting its therapeutic role in the management of SSNHL.
The high degree of heterogeneity observed in this meta-analysis (I2=95.41%) does not invalidate the primary findings. This observation is consistent with the report by Wang, et al. [43], which highlights the absence of a globally accepted standardized protocol for ITSI procedures. This heterogeneity is primarily attributable to variations in the corticosteroid agent, dosage concentration, and injection frequency reported across [44,45].
In clinical practice, the corticosteroid agents most commonly used for ITSI are dexamethasone and methylprednisolone. In the study by Vukelic, et al. [46], intratympanic methylprednisolone was administered at a dose of 125 mg every other day for a total of six injections. Notably, ITSI was utilized both as a first-line therapy in patients with contraindications to systemic corticosteroids and as salvage therapy in patients presenting later after symptom onset. In contrast to the previously described regimen, other studies have employed intratympanic dexamethasone, with considerable variability in dosage concentration and injection frequency across treatment protocols [30,47]. The lack of procedural standardization is likely a major contributor to the substantial heterogeneity reported across meta-analytic studies. Nevertheless, this meta-analysis mitigated such variability by implementing a random-effects model in the statistical analysis. The explicit use of this model accounts for between-study variance, thereby ensuring that the pooled effect estimates remain robust and are not disproportionately influenced by one or two individual studies.
Subgroup analysis further demonstrated no statistically significant difference in treatment effectiveness between patients with moderate-to-severe baseline hearing loss and those with severe initial hearing impairment (p=0.20). This finding suggests that the potential for auditory recovery following ITSI is not solely determined by the severity of baseline hearing loss. These results are supported by the study conducted by Nitta, et al. [48], which evaluated 14 patients with SSNHL presenting with very severe baseline hearing loss. In that study, ITSI treatment resulted in a marked improvement in hearing thresholds, with mean post-intervention thresholds of 65.5±15.2 dB compared to 100.7±5.7 dB prior to intervention. Collectively, these findings provide clinically relevant evidence that patients with severe hearing impairment may achieve hearing recovery outcomes comparable to those with moderate-to-severe hearing loss when treated with appropriately administered intratympanic corticosteroid therapy.
Analysis of clinical phenotype–based subgroups revealed comparable treatment outcomes across different phenotype categories, with no statistically significant differences observed between groups. Two studies conducted by Chen, et al. [33,34] included patients presenting with systemic clinical phenotypes, such as hepatitis B virus infection and diabetes mellitus. Despite these comorbidities, both studies demonstrated that ITSI remained effective in significantly improving hearing thresholds. These findings suggest that the therapeutic efficacy of ITSI may be relatively independent of systemic metabolic or infectious conditions. Zhao, et al. [49] stated that intratympanic steroid therapy has been utilized in patients for whom systemic corticosteroids are contraindicated, including those with immunocompromised conditions, diabetes mellitus, hypertension, peptic ulcer disease, and tuberculosis. The direct delivery of corticosteroids into the middle ear enables high perilymphatic drug concentrations while minimizing systemic exposure, thereby preserving local anti-inflammatory and immunomodulatory effects even in patients with systemic [17-19]. Clinically, this supports the role of ITSI as a valuable treatment option in patients who may be at increased risk of complications from systemic corticosteroid therapy. Nevertheless, the limited number of phenotype-specific studies and potential variability in baseline severity warrant cautious interpretation of these subgroup findings.
In contrast to baseline hearing loss severity and clinical phenotype variables, subgroup analysis based on therapeutic role yielded differential results. In the present review, ITSI demonstrated greater effectiveness when administered as primary (first-line) therapy compared with its use as salvage therapy. The magnitude of the treatment effect observed in the primary therapy subgroup provides supportive evidence for the 2019 Clinical Practice Guidelines issued by the AAO-HNS, which formally recommend ITSI as a first-line therapeutic option for the management of SSNHL [1]. In addition, several previous studies (not included in the present meta-analysis) have reported significant therapeutic benefits when ITSI is administered as primary therapy. Early intervention appears to be particularly critical, as significant hearing improvement was observed when corticosteroids were administered within the first four days of symptom onset (p<0.05) across all evaluated frequencies [50]. Furthermore, a hearing gain of ≥15 dB was achieved in more than 78% of patients following intratympanic methylprednisolone administration, indicating a substantial clinical response. The greater effectiveness observed for primary ITSI compared with salvage ITSI should be interpreted with caution. In the included salvage therapy studies, hearing improvement was generally assessed from the period immediately before salvage ITSI to after completion of salvage treatment. However, patients in the salvage groups had typically received prior systemic steroid or conventional treatment. Therefore, baseline hearing thresholds before salvage ITSI may have already been influenced by previous treatment, making it difficult to completely isolate the therapeutic effect of salvage ITSI alone.
Integrating evidence from the AAO-HNS guidelines with the findings of the present subgroup analysis underscores the therapeutic flexibility of ITSI. ITSI appears to provide substantial clinical benefit when employed as an initial intervention and also remains a valuable salvage option for patients who fail to respond adequately to standard treatment. Notably, in the salvage therapy subgroup, ITSI was associated with meaningful hearing improvement in otherwise refractory cases, consistent with findings reported in previous studies [51].
Overall, the findings of this meta-analysis confirm that ITSI is an effective and versatile therapeutic modality for the management of SSNHL. The intervention demonstrates consistent efficacy across varying baseline hearing levels, clinical phenotypes, and treatment stages, highlighting its broad applicability. Statistical evidence indicates that the therapeutic effectiveness of ITSI is not significantly influenced by baseline hearing loss severity or variations in clinical phenotype. However, differences in treatment context exist between its application as first-line versus salvage therapy, with consistently greater effectiveness observed when ITSI is initiated earlier in the treatment course. These findings carry important clinical implications, suggesting that hearing recovery remains a realistic and worthwhile objective across diverse SSNHL patient profiles, particularly when ITSI is incorporated promptly into the therapeutic strategy.
Despite these encouraging findings, this meta-analysis has several limitations that should be acknowledged. First, interpretation of salvage ITSI outcomes remains challenging because patients had generally received prior systemic steroid or conventional treatment before salvage intervention. Second, the included studies exhibited very high heterogeneity (I2=95.41%). This is likely due to the lack of a standardized ITSI protocol across institutions, including variations in steroid type, concentration, frequency, and timing of administration. Consequently, the findings represent the comprehensive effect of ITSI rather than a specific standardized regimen. Third, restricting the literature search to the last 5 years (2021–2026) ensured the inclusion of recent clinical trends but may have inadvertently excluded foundational or classic studies published prior to this period. Finally, although the Egger regression test indicated no significant publication bias (p= 0.07), the borderline p-value and visual asymmetry in the funnel plot suggest that the possibility of subtle publication bias cannot be entirely ruled out.
In conclusion, this meta-analysis evaluated the effectiveness of ITSI in improving hearing thresholds among patients with SSNHL. Pooled analysis of 16 eligible studies demonstrated that ITSI is associated with a significant and clinically meaningful improvement in hearing outcomes, with a combined effect size of Hedges’ g=-1.05, indicating a large therapeutic effect. This finding was supported by publication bias assessment, suggesting that the pooled estimate is both valid and representative.
The results further indicate that the therapeutic effectiveness of ITSI is not substantially influenced by baseline hearing loss severity (moderate-to-severe versus severe) or by variations in clinical phenotype, supporting the applicability of ITSI across diverse SSNHL patient profiles. These findings underscore the robustness of ITSI as a therapeutic modality irrespective of heterogeneity in clinical presentation.
In contrast, subgroup analysis based on therapeutic role revealed differences in effect magnitude, with ITSI demonstrating a tendency toward greater effectiveness when administered as primary (first-line) therapy compared with its use as salvage therapy. This observation suggests that earlier initiation of ITSI may maximize hearing recovery, while ITSI remains a valuable intervention for patients who do not respond adequately to initial treatment.

Notes

Conflicts of Interest

The authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Nabila Dien Jasmine, Mohammad Ghani. Data curation: Nabila Dien Jasmine, Mohammad Ghani. Formal analysis: all authors. Investigation: all authors. Methodology: Nabila Dien Jasmine, Mohammad Ghani. Resources: all authors. Software: Nabila Dien Jasmine, Mohammad Ghani. Supervision: Mohammad Ghani. Validation: all authors. Visualization: Nabila Dien Jasmine, Mohammad Ghani. Writing—original draft: all authors. Writing—review & editing: all authors. Approval of final manuscript: all authors.

Funding Statement

None

Acknowledgments

None

Fig. 1.
PRISMA flowchart diagram.
jao-2026-00248f1.jpg
Fig. 2.
Forest plot of the effect of ITSI on hearing thresholds. SD, standard deviation; CI, confidence interval; ITSI, intratympanic steroid injection.
jao-2026-00248f2.jpg
Fig. 3.
Funnel plot of overall publication bias. CI, confidence interval.
jao-2026-00248f3.jpg
Fig. 4.
Forest plot of the ITSI effect on hearing thresholds based on mean baseline hearing loss severity. SD, standard deviation; CI, confidence interval; ITSI, intratympanic steroid injection.
jao-2026-00248f4.jpg
Fig. 5.
Forest plot of the ITSI effect on hearing thresholds according to the presence of clinical phenotypes. SD, standard deviation; CI, confidence interval; ITSI, intratympanic steroid injection.
jao-2026-00248f5.jpg
Fig. 6.
Forest plot of ITSI effects on hearing thresholds according to treatment strategy. SD, standard deviation; CI, confidence interval; ITSI, intratympanic steroid injection.
jao-2026-00248f6.jpg
Table 1.
Literature search results
Study (yr) Country Clinical phenotype Treatment strategy Hearing loss severity Intervention Duration
Komatsubara, et al. (2025) [25] Japan NR Salvage Severe ITSI 6 months
Wang, et al. (2025) [26] China NR NR Moderately severe ITSI 2 months 10 days
Chen, et al. (2025a) [33] Taiwan Hepatitis B NR Severe ITSI 72 months
Canakci, et al. (2025) [27] NR NR Primary/first line Moderate ITSI NR
Chen, et al. (2025b) [34] Taiwan Diabetes mellitus NR Severe ITSI 73 months
Aliyeva and Edizer (2024) [28] Turkey - Primary/first line Severe SS+ITSI NR
Ismaiel, et al. (2022) [35] Egypt Labyrinthitis Primary/first line Moderate SS+ITSI NR
Kanotra, et al. (2022) [13] NR NR Primary/first line Severe ITSI 15 months
Kanotra, et al. (2022) [13] NR NR Salvage Severe ITSI 15 months
Kuo, et al. (2024) [24] Taiwan NR Primary/first line Severe ITSI NR
Kuo, et al. (2024) [24] Taiwan NR Salvage Severe ITSI NR
Amizadeh, et al. (2025) [29] Iran NR Primary/first line Moderately severe ITSI 2 months
Seo, et al. (2024) [36] NR Arterial stiffness Salvage Severe ITSI 35 months
Salvador, et al. (2021) [30] NR NR Salvage Severe ITSI NR
Lv, et al. (2022) [31] China NR Salvage Severe ITSI 3 months
Adhikari, et al. (2025) [32] India NR Primary/first line Moderately severe ITSI 6 months

NR, not reported; ITSI, intratympanic steroid injection; SS, systemic steroid.

Table 2.
Statistical analysis of effect sizes across all included studies
Heterogeneity test
Effect size (95% CI) Two-tailed test
I2 (%) p-value Z p-value
95.41 <0.01 -1.05 (-1.45, -0.65) -5.15 <0.01

CI, confidence interval.

Table 3.
Egger test’s result
B1 SE B1 Z p-value
-3.51 1.929 -1.82 0.07
Table 4.
Subgroup analysis based on mean baseline hearing loss severity
Category Heterogeneity test
Effect size (95% CI)
I2 (%) p-value
0=Studies with moderate to severe initial hearing loss (≤70 dB) 95.97 <0.01 -1.53 (-2.60, -0.46)
1=Study with severe initial hearing loss (>70 dB) 87.52 <0.01 -0.80 (-1.08, -0.53)

CI, confidence interval.

Table 5.
Subgroup analysis based on the presence of clinical phenotypes
Category Heterogeneity test
Effect size (95% CI)
I2 (%) p-value
0=Studies without clinical phenotype 92.22 <0.01 -0.96 (-1.33, -0.59)
1=Studies with clinical phenotypes 98.20 <0.01 -1.28 (-2.50, -0.05)

CI, confidence interval.

Table 6.
Subgroup analysis based on treatment strategy
Category Heterogeneity test
Effect size (95% CI)
I2 (%) p-value
0=Primary/first line therapy 96.26 <0.01 -1.24 (-1.83, -0.66)
1=Salvage therapy 14.80 0.13 -0.59 (-0.74, -0.44)

CI, confidence interval.

REFERENCES

1. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg 2019;161(Suppl 1):S1–45.
crossref pmid pmc pdf
2. Kareem RHR, Omer GL, De Donato G, Di Girolamo S, Ali SS, Abdullah AS, et al. Effect of intratympanic steroid injection on hearing loss and tinnitus in sudden sensorineural hearing loss. Aust J Otolaryngol 2025;8:47
crossref
3. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. Otol Neurotol 2013;34:1586–9.
crossref pmid pmc
4. Michel O. [The revised version of the German guidelines “sudden idiopathic sensorineural hearing loss�]. Laryngorhinootologie 2011;90:290–3. German.
pmid
5. Chingath AL, Spoorthi GN, Kalaiah MK, Kumar K, Shastri U. Self-reported communication strategies used by individuals with hearing loss and its influence on the hearing loss related quality of life of their communication partners. Ageing Int 2026;51:8
crossref pdf
6. Bai J, Zhen F, Raneses MDC, Young FC, Yang K. The relationship between hearing loss and cognitive function in the elderly: the mediating effect of social isolation. BMC Geriatr 2025;25:594
crossref pmid pmc pdf
7. Ansari S, Rotenberg BW, Sowerby LJ. Oral corticosteroid prescribing habits of Canadian otolaryngologist-head and neck surgeons. J Otolaryngol Head Neck Surg 2016;45:17
crossref pmid pmc pdf
8. Tejaswini JS, Walia M, Bansal S, Soni S. Efficacy of oral versus intratympanic steroids in the treatment of idiopathic sudden sensorineural hearing loss: a 1-year randomized control trial. Indian J Otol 2023;29:105–10.
crossref pmid
9. Ahn JH. Dexamethasone palmitate: a promising intratympanic treatment option for severe sudden hearing loss. Am J Otolaryngol 2026;47:104766
crossref pmid
10. Shirwany NA, Seidman MD, Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol 1998;19:230–5.
pmid
11. Tsuzuki N, Wasano K. Idiopathic sudden sensorineural hearing loss: a review focused on the contribution of vascular pathologies. Auris Nasus Larynx 2024;51:747–54.
crossref pmid
12. Tatsuno I, Sugiyama T. Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. Diabetes Res Clin Pract 2011;93:e18–20.
crossref pmid
13. Kanotra S, Kumar A, Langar B, Kalsotra P, Paul J. Intratympanic dexamethasone in sudden sensorineural hearing loss. Indian J Otolaryngol Head Neck Surg 2022;74(Suppl 3):3947–56.
crossref pmid pmc pdf
14. Liang S, Li Y, Guo Z, Lu M, Li X, Xu J, et al. Modified intratympanic steroid therapy for sudden sensorineural hearing loss via tympanic tube and gelfoam as a salvage treatment. J Otol 2024;19:19–23.
crossref pmid pmc
15. Ataallah B, Abdulrahman M, Al-Zakhari R, Buttar BS, Nabeel S. Steroid-induced pancreatitis: a challenging diagnosis. Cureus 2020;12:e8939.
crossref pmid pmc
16. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med 2013;173:444–9.
crossref pmid
17. Chang WT, Zee B, Lee HSH, Tong MCF. Dexamethasone eardrop with grommet placement vs intratympanic steroid injection for sudden sensorineural hearing loss: a randomized prospective clinical trial. Am J Otolaryngol 2020;41:102515
crossref pmid
18. Chrysouli K, Kollia P, Papanikolaou V, Chrysovergis A. The effectiveness of intratympanic steroid injection in addition to systemic corticosteroids in the treatment of idiopathic sudden sensorineural hearing loss. Am J Otolaryngol 2023;44:103872
crossref pmid
19. Han JS, Kim YL, Yu HJ, Park JM, Kim YJ, Choung YH, et al. Safety and efficacy of intratympanic histamine injection as an adjuvant to dexamethasone in a noise-induced murine model. Eur J Pharm Sci 2022;178:106291
crossref pmid
20. Lechner M, Sutton L, Ferguson M, Abbas Y, Sandhu J, Shaida A. Intratympanic steroid use for sudden sensorineural hearing loss: current otolaryngology practice. Ann Otol Rhinol Laryngol 2019;128:490–502.
crossref pmid pdf
21. Sturm JJ, Maurrasse SE, Golub JS. Intratympanic steroid injection. Oper Tech Otolaryngol Head Neck Surg 2021;32:92–8.
crossref
22. Lee SY, Seo HW, Jung SM, Lee SH, Chung JH. Assessing the accuracy and reliability of application-based audiometry for hearing evaluation. Sci Rep 2024;14:7359
crossref pmid pmc pdf
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
crossref pmid pmc
24. Kuo LK, Wu JL, Li YL, Hsu HJ. Clinical efficacy of intratympanic steroid injection for treating idiopathic sudden sensorineural hearing loss. J Chin Med Assoc 2024;87:328–33.
crossref pmid pmc
25. Komatsubara Y, Tachibana T, Kataoka Y, Kariya A, Furukawa C, Sato A, et al. Application of intratympanic steroid injection as salvage therapy for idiopathic sudden sensorineural hearing loss. Auris Nasus Larynx 2025;52:248–52.
crossref pmid
26. Wang SY, Fu WT, Yu M, Sun A, Sun J, Li G. Efficacy analysis of intratympanic injection of dexamethasone at different concentrations for the treatment of unilateral idiopathic sudden sensorineural hearing loss. Am J Otolaryngol 2025;46:104603
crossref pmid
27. Canakci H, Arslan E, Tulaci KG, Yazici H. Intratympanic steroid via saturated gelfoam vs. intratympanic injection for sudden sensorineural hearing loss. Auris Nasus Larynx 2025;52:314–8.
crossref pmid
28. Aliyeva A, Edizer DT. Efficacy of intratympanic steroid therapy for severe and profound sudden sensorineural hearing loss. Am J Otolaryngol 2024;45:104170
crossref pmid
29. Amizadeh M, Fazlinezhad F, Ranjbar M, Hasanalifard M. The efficacy of methylprednisolone acetate nanogel in treating patients with sudden sensorineural hearing loss. Sci Rep 2025;15:12342
crossref pdf
30. Salvador P, Moreira da Silva F, Fonseca R. Idiopathic sudden sensorineural hearing loss: effectiveness of salvage treatment with low-dose intratympanic dexamethasone. J Otol 2021;16:6–11.
crossref pmid pmc
31. Lv L, Gao Z, Liu J, Zhuang Y, Hou J, Zhu W, et al. Comparison between postauricular steroid injection and intratympanic steroid perfusion for refractory severe and profound sudden sensorineural hearing loss. Am J Otolaryngol 2022;43:103189
crossref pmid
32. Adhikari S, Bhandari C, Sharma B, Rijal N, Upadhyay HP, Shrestha N. Effectiveness of intratympanic steroid injection in treatment of idiopathic sudden sensorineural hearing loss. J Bharatpur Hosp 2025;1:208–11.
crossref pdf
33. Chen SL, Ho CY, Chin SC, Chan KC, Wang YC. Intratympanic steroid injection for treating sudden sensorineural hearing loss in patients with hepatitis B virus infection. Am J Otolaryngol 2025;46:104660
crossref pmid
34. Chen SL, Ho CY, Chin SC, Chan KC, Wang YC. Sudden sensorineural hearing loss in diabetes mellitus patients receiving intra-tympanic steroid injections. Am J Otolaryngol 2025;46:104576
crossref pmid
35. Ismaiel WF, Abdelazim MH, Wahba AA, Alsobky ME, Ibrahim AA, Ghanem SA, et al. Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases. Ann Med Surg (Lond) 2022;81:104429
crossref pmid pmc
36. Seo HW, Ko SH, Chung JH, Byun H, Shin JH, Lee SH. A prognostic value of estimated pulse wave velocity in idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2024;281:1745–51.
crossref pmid pdf
37. Clark JG. Uses and abuses of hearing loss classification. ASHA 1981;23:493–500.
pmid
38. Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011;305:2071–9.
crossref pmid pmc
39. Devantier L, Callesen HE, Jensen LR, Mirian C, Ovesen T. Intratympanic corticosteroid as salvage therapy in treatment of idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis. Heliyon 2022;8:e08955.
crossref pmid pmc
40. Sakata E, Kitago Y, Murata Y, Teramoto K. [Treatment of Ménière’s disease. Middle ear infusion with lidocaine and steroid solution]. Auris Nasus Larynx 1986;13:79–89. German.
crossref pmid
41. Han CS, Park JR, Boo SH, Jo JM, Park KW, Lee WY, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 2009;141:572–8.
crossref pmid pdf
42. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1–17.
crossref pmid pmc
43. Wang Y, Zhao J, Wu J, Ren T, Wu Y. Comparison of side effects of different steroids used in intratympanic injections. Am J Otolaryngol 2024;45:104258
crossref pmid
44. Okada M, Hato N, Nishio SY, Kitoh R, Ogawa K, Kanzaki S, et al. The effect of initial treatment on hearing prognosis in idiopathic sudden sensorineural hearing loss: a nationwide survey in Japan. Acta Otolaryngol 2017;137(sup565):S30–3.
crossref pdf
45. Amarillo E, Hernández-García E, Herrera M, García Berrocal JR, García Arumí A, Durio E, et al. Sudden hearing loss: national survey in Spain. Acta Otorrinolaringol Esp 2016;67:59–65.
crossref pmid
46. Vukelic J, Marzic D, Liovic A, Manestar D, Anic DM. The effect of aging on hearing outcomes after sudden sensorineural hearing loss (SSNHL): a retrospective study. Arch Gerontol Geriatr 2025;137:105932
crossref pmid
47. Alexander TH, Harris JP, Nguyen QT, Vorasubin N. Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL. Otol Neurotol 2015;36:1321–7.
pmid
48. Nitta Y, Sano H, Kurioka T, Yamashita T. Intratympanic injection of edaravone for idiopathic sudden sensorineural hearing loss with profound hearing loss. J Int Adv Otol 2025;21:1–7.
crossref pmid pmc pdf
49. Zhao D, Tong B, Wang Q, Hellstrom S, Duan M. A comparison of effects of systemic and intratympanic steroid therapies for sudden sensorineural hearing loss: a meta-analysis. J Otol 2016;11:18–23.
crossref pmid pmc
50. Bhandari A, Jain S. Early intratympanic methylprednisolone in sudden SNHL: a frequency-wise analysis. Indian J Otolaryngol Head Neck Surg 2019;71:390–5.
crossref pmid pmc pdf
51. Li P, Zeng XL, Ye J, Yang QT, Zhang GH, Li Y. Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiol Neurootol 2011;16:198–202.
crossref pmid pdf


ABOUT
ARTICLES

Browse all articles >

ISSUES
TOPICS

Browse all articles >

AUTHOR INFORMATION
Editorial Office
SMG–SNU Boramae Medical Center,
20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea
Tel: +82-2-3784-8551    Fax: +82-0505-115-8551    E-mail: jao@smileml.com                

Copyright © 2026 by The Korean Audiological Society and Korean Otological Society. All rights reserved.

Developed in M2PI

Close layer
prev next